Oral formulations and lipophilic salts of methylnaltrexone
AssigneeWyeth
InventorsSyed M. SHAH, Christopher Richard DIORIO, Eric C. EHRNSPERGER, Xu MENG, Kadum A. AL SHAREFFI, Jonathan Marc COHEN
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Claims96
A salt of formula (I):
- wherein A− is an anion of an amphiphilic pharmaceutically acceptable excipient.
(canceled)
(canceled)
A pharmaceutical composition for oral administration comprising a solid dosage of methylnaltrexone or a pharmaceutically acceptable salt thereof, and an amphiphilic pharmaceutically acceptable excipient.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of preparing a methylnaltrexone formulation comprising the steps of:
- preparing a wet granulation comprising methylnaltrexone or a pharmaceutically acceptable salt thereof, an amphiphilic pharmaceutically acceptable excipient, at least one disintegrant, at least one binder, at least one wetting agent, at least one wetting agent, and optionally at least one filler;
- and forming a solid dosage unit.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.